Apple Inc vs Charles River Laboratories Intl. Inc — how do they compare? Apple Inc trades at $303.88 (market cap $4.45T), while Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B). The key difference: Apple Inc is far larger — about 330.6× Charles River Laboratories Intl. Inc's market cap, and Apple Inc pays a 0.35% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AAPL | CRL | |
|---|---|---|
Market Cap | $4.45T | $13.46B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $282.00 |
52-Week Low | $224.90 | $145.57 |
Enterprise Value | $4.47T | $16.30B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →